AXE

0.00%

25.0¢ archer materials limited

Hi Geeris, I deeply appreciate your thoughtful posts…especially...

First 2826 Last

Share
Profile

Follow
Fat Harrys Cat

5,129 Posts.

1093

14/01/24

19:18

Post #: 71873351
Share

Originally posted by Geeris: ↑

Unexplained dips in the sp and we start to question the very capabilities of AXE in every direction. Unexplained rises in the sp don't seem to be for any particular reason either.

Has anything changed with AXE the company and its work. For those of us invested in this for whatever reason, and would rather ignore the shorter term, we probably best read the progress updates when they arrive and keep an eye on the spending in the quarterlies.

Company directions so far, with no indication of any major pivots in strategy -

1. a mobile deployment of 12CQ for maximum addressable market.

2. a mobile deployment of a gFET liquid-gated detection device. Again for maximum units that can be sold.

3. a lab based lab on a chip unit for research and advanced AI diagnostics

These are not trivial endeavours as we have begun to see. It gets very complex very fast. Should these deep tech breakthroughs get to minimum viable products I think they should get bought out. Mo says at every turn, 'we can't do this alone' If and when they do get bought, it's not going to be the current SP on the ASX that decides a price, not with this kind of deep tech. It's going to be because the tech has demonstrated value that the buyer can't get anywhere else. The diagnostics market, point of care market, big pharma, the mobile phone market. Mining and defence industries.

If there are any pivots I anticipate. it's with the biochip strategy. Mo has at times said not to think of the point of care paradigm here. In my opinion this is because a gFET based biosensor device is not cheap to make POC needs affordable devices like lateral flow tests. To get a sheet of graphene on a silicon substrate involves precise positioning of the graphene lattice. Expensive process. Will be interesting to see how much is being spent on the work at different foundries in Europe. A sample wafer is one thing, but reproducing them in bulk is an exercise in expensive quality control. Not to mention electronic optimizations of each batch taking time. Designing workable fluidic channels is also a trial error development phase that no amount of clever machine learning and AI assistance can shorten. Apart from money, TIME has to be spent. There's no other way. Thousands of skilled man hours. Years of development, opportunity cost of staying invested, this is only attractive for the holders.

Expand

Hi Geeris,

I deeply appreciate your thoughtful posts…especially on a Sunday when anything interesting is scarce!
I was intrigued to read that you say Mo has said ”don’t think of the POC paradigm here” regarding the biochip. I must admit that is what I thought it would be developed for. If not for the POC market, then what? Laboratories themselves?
Any thoughts you may offer to reduce my confusion would be appreciated.

Cheers to all,

FHC

AXE Price at posting: 35.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

As Nvidia cools, we're looking to Aussie AI

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

CBA breaks trading record on strong day for Aussie financials

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

There are more pages in this discussion • 830 more messages in this thread...

First 2826 Last

Add AXE (ASX) to my watchlist

(20min delay)
Last 25.0¢		Change 0.000(0.00%)		Mkt cap ! $63.71M

Open	High	Low	Value	Volume
24.5¢	26.0¢	24.5¢	$78.79K	310.0K

Buyers (Bids)

No.	Vol.	Price($)
3	101430	25.0¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	1926	1

View Market Depth

No.	Vol.	Price($)
3	101430	0.250
2	5981	0.245
3	38387	0.240
3	42276	0.235
5	129047	0.230

Price($)	Vol.	No.
0.260	1926	1
0.265	20448	3
0.270	22000	2
0.275	2000	1
0.280	96791	1

Last trade - 16.10pm 06/09/2024 (20 minute delay)

AXE (ASX) Chart

Hi Geeris, I deeply appreciate your thoughtful posts…especially...

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

As Nvidia cools, we're looking to Aussie AI

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

CBA breaks trading record on strong day for Aussie financials

Shekel Brainweigh investor presentation webinar – the future of retail automation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hi Geeris, I deeply appreciate your thoughtful posts…especially...

Top Stories

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

As Nvidia cools, we're looking to Aussie AI

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

CBA breaks trading record on strong day for Aussie financials

Shekel Brainweigh investor presentation webinar – the future of retail automation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News